What alternative treatments should I consider for a patient with restless legs syndrome who is not responding to gabapentin and also has insomnia?

Switch to Pregabalin or Gabapentin Enacarbil and Aggressively Address Iron Deficiency and Insomnia

Your patient requires an immediate switch from gabapentin to either pregabalin or gabapentin enacarbil (both carry strong recommendations as first-line RLS therapy), combined with iron repletion if ferritin ≤100 ng/mL or transferrin saturation <20%, and cognitive behavioral therapy for insomnia (CBT-I) as the primary insomnia intervention. 1, 2

Why Gabapentin May Be Failing

• Gabapentin has variable bioavailability and dose-dependent absorption limitations, whereas gabapentin enacarbil is a prodrug with more predictable pharmacokinetics and pregabalin has linear absorption across the therapeutic range. 1
• All three gabapentinoids (gabapentin, gabapentin enacarbil, pregabalin) receive strong recommendations from the 2025 American Academy of Sleep Medicine guidelines, but switching within the class often yields better results when one agent fails. 1, 3

Step 1: Switch Gabapentinoid Agent

• Discontinue gabapentin and initiate pregabalin 150–300 mg nightly or gabapentin enacarbil 600 mg at 5 PM (taken with food to optimize absorption). 1, 4
• Titrate pregabalin up to 450 mg nightly or gabapentin enacarbil up to 1200 mg if symptoms persist after 1–2 weeks; these agents often require higher doses than clinicians initially prescribe. 1
• Do not add or switch to a dopamine agonist (pramipexole, ropinirole, rotigotine) because they carry a 7–10% annual augmentation risk and are now conditionally recommended against as first-line therapy. 1, 4

Step 2: Measure and Correct Iron Deficiency

• Check serum ferritin and transferrin saturation in the morning after 24 hours of avoiding iron-containing supplements or foods; initiate iron repletion if ferritin ≤100 ng/mL or transferrin saturation <20%. 1, 4
• Intravenous ferric carboxymaltose 1000 mg is the preferred iron formulation (strong recommendation, moderate certainty) because it rapidly corrects deficiency without gastrointestinal side effects. 1, 5
• Oral ferrous sulfate 325–650 mg daily or every other day is an acceptable alternative if IV access is problematic, but expect slower improvement (4–12 weeks vs. weeks with IV iron). 1, 5
• Iron repletion alone can resolve RLS symptoms in iron-deficient patients, eliminating the need for chronic pharmacotherapy. 1

Step 3: Address Insomnia with CBT-I First

• Cognitive behavioral therapy for insomnia (CBT-I) receives a strong recommendation from the American College of Physicians as first-line treatment for chronic insomnia disorder, superior to pharmacologic therapy for long-term outcomes. 2
• CBT-I components include stimulus control, sleep restriction, relaxation strategies, and cognitive restructuring; refer to a behavioral sleep medicine specialist or use digital CBT-I platforms if in-person therapy is unavailable. 2
• If pharmacologic therapy is required for insomnia, consider suvorexant (orexin receptor antagonist), ramelteon (melatonin receptor agonist), or low-dose doxepin (3–6 mg) rather than benzodiazepines or antihistamines, which can worsen RLS. 2, 1
• Avoid diphenhydramine, hydroxyzine, and other centrally acting H1 antihistamines because they exacerbate RLS symptoms. 1, 4

Step 4: Discontinue RLS-Exacerbating Medications

• Immediately stop serotonergic antidepressants (SSRIs, SNRIs), dopamine antagonists (metoclopramide, prochlorperazine), and centrally acting antihistamines if the patient is taking any of these. 1, 4
• Minimize alcohol and caffeine intake, both of which worsen RLS symptoms. 1

Step 5: Screen for Obstructive Sleep Apnea

• Untreated obstructive sleep apnea (OSA) can aggravate RLS and insomnia; screen with validated questionnaires (STOP-BANG) and refer for polysomnography if indicated. 1

Step 6: Reserve Opioids for Refractory Cases

• If symptoms remain refractory after 4–6 weeks of optimized gabapentinoid therapy and iron repletion, add extended-release oxycodone 5–10 mg nightly or methadone 5–10 mg nightly (conditional recommendation, moderate certainty). 1, 4
• Opioids have minimal augmentation risk compared to dopamine agonists and are now preferred second-line agents for severe or refractory RLS. 1, 6

Critical Pitfalls to Avoid

• Do not start a dopamine agonist before correcting iron deficiency; this exposes the patient to augmentation risk while a safer, disease-modifying intervention (iron repletion) is available. 1
• Do not use benzodiazepines (e.g., clonazepam) as primary RLS therapy; they do not address the underlying sensorimotor disorder and carry dependence risk. 1
• Do not prescribe antihistamines (diphenhydramine, doxylamine) for insomnia in RLS patients; they worsen restless legs symptoms. 1, 4
• Do not assume gabapentin failure means all gabapentinoids will fail; switching to pregabalin or gabapentin enacarbil often succeeds. 1

Summary Algorithm

1. Switch to pregabalin 150–450 mg nightly or gabapentin enacarbil 600–1200 mg at 5 PM. 1
2. Check ferritin and transferrin saturation; give IV ferric carboxymaltose 1000 mg if ferritin ≤100 ng/mL or TSAT <20%. 1, 5
3. Initiate CBT-I for insomnia; add suvorexant, ramelteon, or low-dose doxepin only if CBT-I is insufficient. 2
4. Discontinue any RLS-exacerbating medications (SSRIs, antihistamines, dopamine antagonists). 1
5. Screen for and treat OSA if present. 1
6. If refractory after 4–6 weeks, add extended-release oxycodone 5–10 mg or methadone 5–10 mg nightly. 1, 4